The challenge
By the 1960s malaria parasites were increasingly resistant to chloroquine, the main drug of the era, and quinine was losing ground in some regions. Soldiers and civilians in Southeast Asia were suffering, and China received a request for help from North Vietnam. In response, a military-led, secret national effort called Project 523 began on 23 May 1967. After nearly two years and a very large number of tested molecules, it had not produced a usable drug. The challenge was to find a medicine that worked against drug-resistant malaria, was safe enough for people, and could be produced in quantity, while the country was in political upheaval and its research system was disrupted.
The people
Tu Youyou, born in 1930 in Ningbo, was a researcher at the Institute of Chinese Materia Medica in Beijing. In 1969 she was appointed to lead the institute's Project 523 group, which combined practitioners of traditional medicine with chemists and pharmacologists. The Lasker Foundation notes that many scientists at other institutes contributed to improved extraction and to clinical trials, and it names colleagues such as Zhong Yurong, who obtained crystalline samples in 1972. Guoqiao Li and others carried out important later clinical work on derivatives. Project 523 itself involved many institutions across China. The 2015 Nobel Prize in Physiology or Medicine was awarded one half to Tu, and the other half jointly to William Campbell and Satoshi Omura for a different antiparasitic medicine, ivermectin.
The contribution
Tu's group collected around two thousand remedies from classical texts and folk sources and prepared hundreds of extracts from about two hundred herbs. A sweet wormwood (qinghao) extract looked promising in 1971 but gave inconsistent results. Returning to the literature, Tu noted an old handbook attributed to Ge Hong (c. 340 CE) that described soaking the plant in cold water rather than boiling it. Her team switched to low-temperature extraction and used ether, then removed acidic components that were toxic. In 1972 an extract cleared parasites in animals, and trials in Hainan showed fast clearing of fever and parasites in patients. On 8 November 1972 the group obtained the pure compound, which became known as artemisinin. Later derivatives and combination therapies are now recommended by the World Health Organization.
The wider context
Project 523 was a government mobilization in which science was organized around a military and humanitarian priority, during the Cultural Revolution, when universities and journals were disrupted. Tu was working in a research culture that valued collective achievement: the first papers on artemisinin were published without individual author names, and scientific results were credited to institutions. Her work also sits within a global story of antimalarial drugs: quinine from cinchona bark, the synthetic drugs of the twentieth century, and the rise of resistance. Artemisinin is a plant-derived compound with an unusual peroxide chemical structure, and it was identified at a moment when Western and Chinese science had little contact. Its acceptance abroad came later, after English-language reports in 1979 and presentations to a WHO-sponsored group in 1981.
Obstacles along the way
Tu's own account and later reviews stress that the early results could not be reproduced until the extraction method changed. The team tested the extract on themselves before large patient trials, which shows how difficult conditions were and also why modern ethics rules matter. Credit remains an area of friction. Because the early papers were anonymous and the work was collective, accounts differ on how much weight to put on Tu versus other team members and institutions; the Lasker and Nobel awards recognized her leadership, and the Lasker page also names a number of colleagues, but many contributors remain unnamed in popular accounts. The medicine also has limits. Artemisinin is cleared from the body quickly, so it is used with partner drugs in combination therapy, and researchers continue to monitor signs of delayed parasite clearance. Malaria still kills many people, especially young children in Africa.
Why it matters
Artemisinin-based combination therapies are recommended by the WHO as first-line treatment for the most dangerous form of malaria, and the Nobel Committee has estimated that these therapies have saved large numbers of lives, including more than 100,000 a year in Africa alone. Beyond the numbers, the story shows how traditional knowledge and modern laboratory methods can inform one another when each is examined critically. It was a text that suggested a better extraction method, but it took modern chemistry, controlled testing and clinical trials to turn a lead into a medicine. It also illustrates how a drug can be both a triumph and a continuing responsibility: resistance, supply and access all need ongoing attention.
What we can learn
Treat old texts as clues, not proof, and treat modern tests as essential. Notice that a promising result that cannot be repeated is not yet a finding; Tu's group had to work out why. Pay attention to how credit is assigned in large projects, and who may be missing from the standard story. Consider the ethics of early human testing and why modern oversight developed. And note the public-health lesson: effective treatments need strategies to prevent resistance, which is why combination therapy and careful use matter. This is educational background, not medical advice; anyone concerned about malaria should consult a health professional or national health authority.
